Xtant Medical Inc.

AI Score

0

Unlock

0.55
0.05 (10.00%)
At close: Jan 14, 2025, 3:57 PM
0.51
-7.23%
After-hours Jan 14, 2025, 08:00 PM EST
undefined%
Bid 0.5
Market Cap 75.90M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -0.13
PE Ratio (ttm) -4.2
Forward PE n/a
Analyst Strong Buy
Ask 0.8
Volume 48,304
Avg. Volume (20D) 137,311
Open 0.47
Previous Close 0.50
Day's Range 0.47 - 0.55
52-Week Range 0.33 - 1.30
Beta undefined

About XTNT

Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect ...

Sector Healthcare
IPO Date Jul 1, 2010
Employees 207
Stock Exchange AMEX
Ticker Symbol XTNT

Analyst Forecast

According to 1 analyst ratings, the average rating for XTNT stock is "Strong Buy." The 12-month stock price forecast is $3, which is an increase of 449.45% from the latest price.

Buy 100.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Xtant Medical Inc. is scheduled to release its earnings on Mar 31, 2025, before market opens.
Analysts project revenue of $30.90M, reflecting a 9.93% YoY growth and earnings per share of -0.01, making a -66.67% decrease YoY.
9 months ago · Source
Xtant Medical Holdings shares are trading lower af... Unlock content with Pro Subscription